In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Heyday of Biotech Dealmaking

Executive Summary

Deal values and perks are up for biotechs; the Pharmaceutical Strategic Outlook conference suggests Big Pharma might begin to borrow some biotech strategies.

Related Content

The Value of Drug Repositioning: Longer Patent Life
Lilly's Chorus Experiment
Reviewing Five Years of Big Pharma's Biotech Acquisitions
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
The $100 Million IND
The $100 Million IND
Pfizer's Change Management: Unfamiliar Faces
Pfizer's Change Management: Unfamiliar Faces


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts